Biovision
BioSim™ anti-Adalimumab (Humira®) (Human) ELISA Kit
- SKU:
- 26-E4388
- Availability:
- Usually Shipped in 5 Working Days
- Size:
- 100 Assays
- Storage Conditions:
- 4°C
- Shipping Conditions:
- Gel Pack
- Shelf life:
- 12 months
Description
Adalimumab (Humira®) is a recombinant human IgG1 monoclonal antibody specific for Tumor Necrosis Factor-Alpha (TNF-α) and is used to treat rheumatic arthritis, intestinal disorders, dermatological diseases and cancer. Adalimumab specifically binds to TNF alpha and blocks its interaction with p55 and p75 cell surface TNF receptors and reduces the inflammation and subsequently improves the patient’s health. Drug level quantification can be important to adapt patient prescription or to switch to an alternative TNF inhibitor drug. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Adalimumab ELISA kit is designed to quantify/measure the antibody against Adalimumab with high specificity and sensitivity in biological matrices.
Alternate Name: N/A
Tag Line: A Sandwich ELISA kit for the quantitative measurement of antibody against Adalimumab in human serum or plasma.
Summary: • Detection method- Absorbance (450 nm) • Species reactivity- Human • Application- quantitative measurement of antibody against Adalimumab in human serum and plasma
Detection Method: Absorbance (450 nm)
Sample Type: Human serum and plasma
Species Reactivity: Human
Applications: This ELISA kit is used for quantitative measurement of antibody against Adalimumab in human serum and plasma
Features & Benefits: Easy, convenient, sensitive and time-saving method to measure the level of antibody against Adalimumab in human serum and plasma. Detection Range: 62 - 500 ng/ml Sensitivity: 30 ng/ml Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100) Cross Reactivity: Adalimumab infusion camouflages/masks the presence of antibody to adalimumab (ATA) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATA. It is convenient to obtain blood sample just before the infusion of adalimumab or at least 2 weeks after the infusion of adalimumab. Recovery rate: 85 – 115% with normal human serum samples with known concentrations